Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 17Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1Classical hematology 1CNS 1Breast 1

Conditions

Glioma 1Glioblastoma 1

Interventions

Temozolomide 147Radiotherapy 91Cyclophosphamide 53Magnetic Resonance Spectroscopy 43Radiation 42Bevacizumab 38Irinotecan 34Filgrastim 29Radiosurgery 27Specimen Handling 25Nivolumab 25Carboplatin 24Topotecan 23Etoposide 22fludarabine 20Surgical Procedures, Operative 20pembrolizumab 19Vorinostat 18Vincristine 18Melphalan 17Granulocyte Colony-Stimulating Factor 17sargramostim 15Peripheral Blood Stem Cell Transplantation 14Ipilimumab 14Drug Therapy 13temsirolimus 12Sirolimus 12Radiotherapy, Intensity-Modulated 12O(6)-benzylguanine 12Everolimus 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × bicalutamide × CNS × Clear all
NCT06501911 2025-07-22

A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma

University of Nebraska

Phase 1 Withdrawn
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡